{"publication_id":"d8263221-9f0a-41ec-95ec-4711d2e47db6","screening":{"identified":16,"screened":16,"excluded":0,"included":16,"included_or_retained":16,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"16 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The conclusion is that deuterium depleted water should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","The curated corpus lacks any randomized controlled trial of deuterium-depleted water (DDW) and is instead composed entirely of observational cohorts and preclinical models. All clinical evidence derives from uncontrolled designs in which DDW was administered alongside conventional cancer therapy (Somlyai 2025, Somlyai 2023, Boros 2021), making it impossible to isolate the independent contribution of deuterium depletion to the reported survival outcomes. Consequently, the headline conclusion that DDW \"multiplies survival probability\" rests on evidence that cannot meet conventional efficacy thresholds for causal inference.","Several clinically relevant endpoints are represented by only a single source, precluding internal replication within the corpus. The cardiometabolic outcome class—specifically GLUT4 translocation and insulin-sensitivity markers—is supported by one laboratory study (Kondo 2024) and one preclinical investigation (Molnar 2021), but no human trial has confirmed these glucose-uptake findings in vivo. Immune-inflammation endpoints are likewise touched by a single preclinical source (Rasooli 2019) examining sepsis-induced liver injury in rats, with no corroborating clinical data. Translational relevance to humans remains uncertain. When outcomes depend on lone studies, effect estimates cannot be triangulated and the risk of spurious or context-specific findings remains unquantifiable.","The population base is narrow, restricting external validity. Clinical cohorts enrolled exclusively adult cancer patients—primarily lung, pancreatic, and glioblastoma subtypes (Somlyai 2025, Somlyai 2023, Boros 2021, Gyongyi 2013)—with no evidence in pediatric, pregnant, or elderly non-oncologic populations. Geographic and institutional diversity is also limited; the Hungarian research group behind Somlyai 2025 and Somlyai 2023 accounts for a substantial share of the clinical data, and independent replication outside this network is absent from the corpus. Preclinical animal studies used young-adult rodents (Halenova 2019, Basov 2019), whose metabolic and deuterium-turnover kinetics may not generalize to aged or metabolically compromised humans. The obesity-relevant rat model (Halenova 2019) demonstrated restored body-weight index and serotonin levels after 3 weeks of DDW at 10 ppm, yet no parallel human dietary-intervention trial exists to bridge this finding.","The corpus contains a pronounced mechanism-to-clinic gap: cell-level and animal-model evidence for DDW's anticancer and metabolic mechanisms is relatively rich, but corresponding clinical-effectiveness data are sparse. Similarly, DDW-induced GLUT4 translocation and a reported three- to four-fold increase in glucose uptake under insulin-resistant conditions (Kondo 2024) have not been validated against hard cardiometabolic endpoints such as HbA1c reduction toward the 7% target recommended by ADA 2024. Long-term safety data, dose–response characterization in humans, and quality-of-life outcomes are entirely absent from the curated references. Until controlled trials bridge these mechanistic observations to patient-centered endpoints, the therapeutic promise of deuterium-depleted water remains plausible but unproven.","For deuterium depleted water, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support deuterium depleted water as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 16 curated reference papers, the evidence base for Deuterium depleted water shows a context-dependent profile. Null findings dominate: contextual other, mortality survival. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Deuterium depleted water anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}